Antibiotics are lifesaving therapeutic drugs that have been used by human for decades.
They are used both in the fight against bacterial pathogens for both human and for animal …

Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …

Patients with Parkinson's disease (PD) exhibit distinct gut microbiota, which may promote
gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut …

Background The gut microbiota represents a potential treatment target in heart failure (HF)
through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic …

Ethical practices in human microbiome research have failed to keep pace with scientific
advances in the field. Researchers seeking to 'preserve'microbial species associated with …

Common variable immunodeficiency (CVID) is the most common symptomatic primary
antibody immunodeficiency, characterized by reduced serum levels of IgG, IgA, and/or IgM …

A substantial proportion of patients with common variable immunodeficiency (CVID) have
inflammatory and autoimmune complications of unknown etiology. We have previously …

Probiotics and postbiotics have emerged as an alternative to traditional antibiotics for the
treatment of persistent skin infections. The use of probiotics and postbiotics has been shown …

Introduction Patients with common variable immunodeficiency (CVID) have a high frequency
of inflammatory complications like autoimmune cytopenias, interstitial lung disease and …

Though ursodeoxycholic acid (UDCA) remains the baseline treatment for most cholestatic
liver diseases, UDCA treatment leaves approximately one-third of patients with primary …